Understanding the contribution of MMP-2 to tumor immune evasion and its association with poor clinical outcomes could provide a compelling rationale for targeting MMP-2 in combination with ICIs, potentially offering a novel therapeutic strategy to overcome resistance and improve the efficacy of immunotherapy in COAD. Here, MMP2 is linked to colon adenocarcinoma.